Luke Timmerman at Xconomy wrote a provocative piece today entitled The Missing Ingredient in Today's Biotech: Guts. His thesis is that the industry is so paralyzed by fear and insecurity that it lacks…
The pharmaceutical industry has benefitted mankind by developing life-saving and life-sustaining drugs. However, recent turmoils have led many to question the value provided by the industry. Matt Herper tackles these complex issues across two blog posts.
The June, 2011 issue of Nature Drug Discovery has a interesting short article based on a survey conducted by our good friends at PharmaVentures. The authors surveyed 180 business development…
Bruce Booth from Atlas Ventures has a fascinating story on his blog. We won't steal Bruce's thunder. Instead, we encourage you to read it there first. The gist of the story is…
Bloomberg has a good round up of several emerging pharmaceutical companies developing antibiotics. As the article notes, Big Pharma has largely moved away from antibiotic development for a number of…
There is an excellent editorial in the May issue of Nature Biotechnology entitled Inadequately met needs. In it, the author points out that the US is moving away from innovative,…
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
Fred Frank, a highly respected investment banker, greeted us on Tuesday morning with this missive: Venture capitalists, who make high-risk investments in start-ups, are tired of waiting years for biotech companies…
It was recently announced that the EMA has rejected Xyrem for the treatment of fibromyalgia. Interestingly, Xyrem is already approved in Europe for the treatment of narcolepsy with cataplexy. We…
Drug development costs of $1 billion are often quoted. A new study estimates costs to be much lower, based on a different statistical approach.